Hemotrax 500 mg/5 ml (IM/IV Injection)
Medicine Details
| Category | Details |
|---|---|
| Generic | Tranexamic acid |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Product Title
Hemotrax
Categories
- Medicine
- Pharmacology
- Hemostatic Drugs
- Anti-fibrinolytic Drugs
Description
Hemotrax is a preparation of tranexamic acid, used for prophylaxis and therapy of various hemorrhagic conditions in medicine, surgery, urology, obstetrics, otorhinolaryngology, stomatology, and oncology. It has strong antifibrinolytic action and low acute and chronic toxicity. The usual adult dose is 500-1000 mg 3 times daily.
Indications
- Prophylaxis and therapy of hemophtoes
- Digestive hemorrhages
- Hemorrhagic syndromes in leukaemia
- Accidents during thrombolytic therapy
- Prophylaxis and antihemorrhagic therapy during operations of any type
- Prophylaxis and antihemorrhagic therapy of prostatic, vesical and renal surgery
- Prophylaxis and therapy of post-partum and puerperium hemorrhages
- Prophylaxis and antihemorrhagic therapy during a tonsillectomy
- Prophylaxis and antihemorrhagic therapy during maxillofacial operations
- To promote the formation of a fibrin capsule to inhibit the growth of ovarian tumors
- To cause regression of ascites secondary to carcinoma
- To reduce bleeding during surgical interventions
Pharmacology
Tranexamic acid has an antifibrinolytic action, inhibiting plasminogen activation. It is well absorbed orally, excreted mainly by renal route, and does not interfere with clotting processes.
Dosage and Administration
- Adults:
- Usual dose: 500-1000 mg 3 times daily
- Prophylaxis: 0.5-1 gm orally, 500 mg by the parenteral route
- Therapy of hemorrhagic manifestations: 1-3 gm given in divided doses
- Children:
- Prophylaxis dose: 5-10 mg per kg of body weight daily
- Therapeutic doses: Doubled oral doses, initial intravenous and intramuscular treatment
- Elderly patients: No reduction in dosage unless evidence of renal failure
Interaction
Incompatible with solutions containing penicillins. Antagonized by thrombolytic drugs. Potential for thrombus formation increased by estrogen-containing drugs. Avoid direct admixture with whole blood during transfusion.
Contraindications
- Known individual hypersensitivity
- Thromboembolic disease
- Arterial and venous thrombosis
- Endocavitary hemorrhages
- Serious kidney failure
Side Effects
- Sense of fatigue
- Conjunctival irritation
- Nasal blockage
- Itching
- Skin reddening
- Exanthems
- Nausea
- Diarrhea
- Gastric pyrosis
- Postural hypotension
- Hypersensitivity reactions
Pregnancy and Lactation
Not recommended during known and presumed pregnancy. Passes into breast milk to a low concentration unlikely to have antifibrinolytic effect in the infant.
Precautions and Warnings
- Use in cases of hyperfibrinolysis
- Prophylactic treatment must begin 24 hours before operation
- Prolong therapy of hemorrhages for at least 24 hours after manifestations disappear
- Reduce doses in hematuria to prevent clot formation in urinary tract
- Avoid use in serious renal insufficiency
- Use with caution in less serious renal dysfunctions
- Care in cardiopathic and hepatopathic subjects
Therapeutic Class
- Anti-fibrinolytic drugs
- Haemostatic drugs
Storage Conditions
Store in a dry place at 15-30°C, away from light, and keep out of children's reach